Theoretical analysis of alendronate and risedronate effects on canine vertebral remodeling and microdamage

Journal of Biomechanics

Volumn 42, Issue 7, 2009, Pages 938-944

  Wang, Xiang ^a   Erickson, Antonia M ^a   Allen, Matthew R ^b   Burr, David B ^b   Martin, R Bruce ^a   Hazelwood, Scott J ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c CALIFORNIA POLYTECHNIC STATE UNIVERSITY   (United States)

Author keywords

Alendronate; Bisphosphonate; BMU; Bone remodeling; Canine; Microdamage; Risedronate; Simulation

Indexed keywords

ALENDRONATE; BISPHOSPHONATE; BMU; BONE REMODELING; CANINE; MICRODAMAGE; RISEDRONATE; SIMULATION;

ELECTRIC NETWORK ANALYSIS; RISK PERCEPTION; STRAIN RATE; TITRATION;

BONE;

ALENDRONIC ACID; RISEDRONIC ACID;

ANIMAL EXPERIMENT; ARTICLE; BONE INJURY; CONTROLLED STUDY; EXPERIMENTAL DOG; FEMALE; MATHEMATICAL MODEL; NONHUMAN; OSTEOLYSIS; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; SIMULATION; THEORETICAL STUDY; TRABECULAR BONE; VALIDATION STUDY; VERTEBRA BODY;

ALENDRONATE; ANIMALS; COMPUTER SIMULATION; DISEASE MODELS, ANIMAL; DOGS; ETIDRONIC ACID; FRACTURES, BONE; SPINE; SUBSTRATE SPECIFICITY;

EID: 64549137196     PISSN: 00219290     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jbiomech.2008.07.039     Document Type: Article

References (42)

1. Allen M.R., and Burr D.B. Three years of alendronate treatment results in similar levels of vertebral microdamage as after one year of treatment. Journal of Bone and Mineral Research 22 11 (2007) 1759-1765
2. Allen M.R., Iwata K., Phipps R., and Burr D.B. Alterations in canine vertebral bone turnover, microdamage accumulation, and biomechanical properties following 1-year treatment with clinical treatment doses of risedronate and alendronate. Bone 39 4 (2006) 872-879
3. Beaupre G.S., Orr T.E., and Carter D.R. An approach for time-dependent bone modeling and remodeling-application: a preliminary remodeling simulation. Journal of Orthopaedic Research 8 5 (1990) 662-670
4. Boivin G.Y., Chavassieux P.M., Santora A.C., Yates J., and Meunier P.J. Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women. Bone 27 5 (2000) 687-694
5. Bone H.G., Hosking D., Devogelaer J.P., Tucci J.R., Emkey R.D., Tonino R.P., Rodriguez-Portales J.A., Downs R.W., Gupta J., Santora A.C., Liberman U.A., and Alendronate Phase III Osteoporosis Treatment Study Group. Ten years' experience with alendronate for osteoporosis in postmenopausal women. New England Journal of Medicine 350 12 (2004) 1189-1199
6. Borah B., Dufresne T.E., Ritman E.L., Jorgensen S.M., Liu S., Chmielewski P.A., Phipps R.J., Zhou X., Sibonga J.D., and Turner R.T. Long-term risedronate treatment normalizes mineralization and continues to preserve trabecular architecture: sequential triple biopsy studies with micro-computed tomography. Bone 39 2 (2006) 345-352
7. Boyce R.W., Paddock C.L., Gleason J.R., Sletsema W.K., and Eriksen E.F. The effects of risedronate on canine cancellous bone remodeling: three-dimensional kinetic reconstruction of the remodeling site. Journal of Bone and Mineral Research 10 2 (1995) 211-221
8. Burr D.B., Martin R.B., Schaffler M.B., and Radin E.L. Bone remodeling in response to in vivo fatigue microdamage. Journal of Biomechanics 18 (1985) 189-200
9. Chavassieux P.M., Arlot M.E., Reda C., Wei L., Yates A.J., and Meunier P.J. Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis. Journal of Clinical Investigation 100 (1997) 1475-1480
10. Chavassieux P.M., Arlot M.E., Roux J.P., Portero N., Daifotis A., Yates A.J., Hamdy N.A., Malice M.P., Freedholm D., and Meunier P.J. Effects of alendronate on bone quality and remodeling in glucocorticoid-induced osteoporosis: a histomorphometric analysis of transiliac biopsies. Journal of Bone and Mineral Research 15 (2000) 754-762
11. Day J.S., Ding M., Bednarz P., van der Linden J.C., Mashiba T., Hirano T., Johnston C.C., Burr D.B., Hvid I., Sumner D.R., and Weinans H. Bisphosphonate treatment affects trabecular bone apparent modulus through micro-architecture rather than matrix properties. Journal of Orthopaedic Research 22 3 (2004) 465-471
12. Delmas P.D. How does antiresorptive therapy decrease the risk of fracture in women with osteoporosis?. Bone 27 (2000) 1-3
13. Ding M., Day J.S., Burr D.B., Mashiba T., Hirano T., Weinans H., Sumner D.R., and Hvid I. Canine cancellous bone microarchitecture after one year of high-dose bisphosphonates. Calcified Tissue International 72 6 (2003) 737-744
14. Dufresne T.E., Chmielewski P.A., Manhart M.D., Johnson T.D., and Borah B. Risedronate preserves bone architecture in early postmenopausal women in 1 year as measured by three-dimensional microcomputed tomography. Calcified Tissue International 73 5 (2003) 423-432
15. Eriksen E.F., Melsen F., Sod E., Barton I., and Chines A. Effects of long-term risedronate on bone quality and bone turnover in women with postmenopausal osteoporosis. Bone 31 (2002) 620-625
16. Forwood M.R., Burr D.B., Takano Y., Eastman D.F., Smith P.N., and Schwardt J.D. Risedronate treatment does not increase microdamage in the canine femoral neck. Bone 16 6 (1995) 643-650
17. Frost H.M. Tetracycline-based histological analysis of bone remodeling. Calcified Tissue International 3 (1969) 211-237
18. Frost H.M. Osteoporoses: a rationale for further definitions?. Calcified Tissue International 62 2 (1998) 89-94
19. Hazelwood S.J., Martin R.B., Rashid M.M., and Rodrigo J.J. A mechanistic model for internal bone remodeling exhibits different dynamic responses in disuse and overload. Journal of Biomechanics 34 (2001) 299-308
20. Hirano T., Turner C.H., Forwood M.R., Johnston C.C., and Burr D.B. Does suppression of bone turnover impair mechanical properties by allowing microdamage accumulation?. Bone 27 1 (2000) 13-20
21. Komatsubara S., Mori S., Mashiba T., Ito M., Li J., Kaji Y., Akiyama T., Miyamoto K., Cao Y., Kawanishi J., and Norimatsu H. Long-term treatment of incadronate disodium accumulates microdamage but improves the trabecular bone microarchitecture in dog vertebra. Journal of Bone and Mineral Research 18 3 (2003) 512-520
22. Komatsubara S., Mori S., Mashiba T., Li J., Nonaka K., Kaji Y., Akiyama T., Miyamoto K., Cao Y., Kawanishi J., and Norimatsu H. Suppressed bone turnover by long-term bisphosphonate treatment accumulates microdamage but maintains intrinsic material properties in cortical bone of dog rib. Journal of Bone and Mineral Research 19 (2004) 999-1005
23. Martin R.B. The usefulness of mathematical models for bone remodeling. Yearbook of Physical Anthropology 28 (1985) 227-236
24. Martin R.B. Mathematical model for repair of fatigue damage and stress fracture in osteonal bone. Journal of Orthopaedic Research 13 (1995) 309-316
25. Mashiba T., Hirano T., Turner C.H., Forwood M.R., Johnston C.C., and Burr D.B. Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib. Journal of Bone and Mineral Research 15 4 (2000) 613-620
26. Mashiba T., Mori S., Burr D.B., Komatsubara S., Cao Y., Manabe T., and Norimatsu H. The effects of suppressed bone remodeling by bisphosphonates on microdamage accumulation and degree of mineralization in the cortical bone of dog rib. Journal of Bone and Mineral Research 23 Supplement (2005) 36-42
27. Mashiba T., Turner C.H., Hirano T., Forwood M.R., Johnston C.C., and Burr D.B. Effects of suppressed bone turnover by bisphosphonates on microdamage accumulation and biomechanical properties in clinically relevant skeletal sites in beagles. Bone 28 (2001) 524-531
28. Miller P.D., Watts N.B., Licata A.A., Harris S.T., Genant H.K., Wasnich R.D., Ross P.D., Jackson R.D., Hoseyni M.S., Schoenfeld S.L., Valent D.J., and Chesnut C.H. Cyclical etidronate in the treatment of postmenopausal osteoporosis: efficacy and safety after seven years of treatment. American Journal of Medicine 103 6 (1997) 468-476
29. Moore T.L.A., and Gibson L.J. Microdamage accumulation in bovine trabecular bone in uniaxial compression. Journal of Biomechanical Engineering-Transactions of the ASME 124 1 (2002) 63-71
30. Mori S., and Burr D.B. Increased intracortical remodeling following fatigue damage. Bone 14 (1993) 103-109
31. Nyman J.S., Rodrigo J.J., Hazelwood S.J., Yeh O.C., and Martin R.B. Predictions on preserving bone mass in knee arthroplasty with bisphosphonates. Journal of Arthroplasty 21 1 (2006) 106-113
32. Nyman J.S., Yeh O.C., Hazelwood S.J., and Martin R.B. A theoretical analysis of long-term bisphosphonate effects on trabecular bone volume and microdamage. Bone 35 (2004) 296-305
33. Porras A.G., Holland S.D., and Gertz B.J. Pharmacokinetics of alendronate. Clinical Pharmacokinetics 36 (1999) 315-328
34. Recker R.R., Gallagher R., and MacCosbe P.E. Effect of dosing frequency on bisphosphonate medication adherence in a large longitudinal cohort of women. Mayo Clinic Proceedings 80 7 (2005) 856-861
35. Rodan G.A., and Fleisch H.A. Bisphosphonates: mechanisms of action. Journal of Clinical Investigation 97 12 (1996) 2692-2696
36. Schaffler M.B., Choi K., and Milgrom C. Aging and matrix microdamage accumulation in human compact bone. Bone 17 (1995) 521-525
37. Ste-Marie L.G., Sod E., Johnson T., and Chines A. Five years of treatment with risedronate and its effects on bone safety in women with postmenopausal osteoporosis. Calcified Tissue International 75 6 (2004) 469-476
38. Storm T., Steiniche T., Thamsborg G., and Melsen F. Changes in bone histomorphometry after long-term treatment with intermittent, cyclic etidronate for postmenopausal osteoporosis. Journal of Bone and Mineral Research 8 (1993) 199-208
39. Tonino R.P., Meunier P.J., Emkey R., Rodriguez-Portales J.A., Menkes C.J., Wasnich R.D., Bone H.G., Santora A.C., Wu M., Desai R., and Ross P.D. Skeletal benefits of alendronate: 7-year treatment of postmenopausal osteoporotic women. Phase III osteoporosis treatment study group. Journal of Clinical Endocrinology and Metabolism 85 9 (2000) 3109-3115
40. Wang X., and Niebur G.L. Microdamage propagation in trabecular bone due to changes in loading mode. Journal of Biomechanics 39 (2006) 781-790
41. Whalen R.T., Carter D.R., and Steele C.R. Influence of physical activity on the regulation of bone density. Journal of Biomechanics 21 10 (1988) 825-837
42. Zoehrer R., Roschger P., Paschalis E.P., Hofstaetter J.G., Durchschlag E., Fratzl P., Phipps R., and Klaushofer K. Effects of 3- and 5-year treatment with risedronate on bone mineralization density distribution in triple biopsies of the iliac crest in postmenopausal women. Journal of Bone and Mineral Research 21 7 (2006) 1106-1112